Cryptococcal cellulitis in a lung-transplant recipient [2]

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 1068-1070

  Geusau, A ^a   Sandor, N ^a   Messeritsch, E ^a   Jaksch, P ^b   Tintelnot, K ^c   Presterl, E ^b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; ANAMNESIS; CASE REPORT; CELLULITIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCUS NEOFORMANS; DNA FINGERPRINTING; FEMALE; FUNGAL CELL; HUMAN; LABORATORY TEST; LETTER; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN BIOPSY;

CELLULITIS; CRYPTOCOCCOSIS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LEG DERMATOSES; LUNG TRANSPLANTATION; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 27544498009     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06894.x     Document Type: Letter

References (11)

1. Lemmer K, Naumann D, Raddatz B, Tintelnot K. Molecular typing of Cryptococcus neoformons by PCR fingerprinting, in comparison to serotyping and Fourier transform infrared-spectroscopy-based phenotyping. Med Mycol 2004; 42:135-47.
2. Neuville S, Dromer F, Morin O et al. and the French Cryptococcosis Study Group. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337-47.
3. Revenga F, Paricio JF, Merino FJ et ai. Primary cutaneous cryptococcosis in an immunocompetent host: case report and review of the literature. Dermatology 2002; 204:145-9.
4. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001; 7:375-81.
5. Thomas I, Schwanz RA. Cutaneous manifestations of systemic cryptococcosis in immunosuppressed patients. J Med 2001; 32: 259-66.
6. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-18.
7. Sheng WH, Hung CC, Chen MY et al. Successful discontinuation of fluconazole as secondary prophylaxis for cryptococcosis in AIDS patients responding to highly active antiretroviral therapy. Int J STD AIDS 2002; 13:702-5.
8. Hamann ID, Gillespie RJ, Ferguson JK. Primary cryptococcal cellulitis caused by Cryptococcus neoformans var. gottii in an immunocompetent host. Australas J Dermatol 1997; 38:29-32.
9. FIMUA Cryptococcosis Network European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: report from Italy. Med Mycol 2002; 40:507-17.
10. Dromer F, Mathoulin S, Dupont B et al. Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis 1996; 23:91-6.
11. Tintelnot K, Lemmer K, Losert H et al. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses 2004; 47:455-64.